Skip to main content

Clinical Trials to Treat Adult Metastatic Brain Tumors

Trials 26-50 of 68

Adagrasib plus Stereotactic Radiosurgery for the Treatment of KRAS G12C-Mutated Non-small Cell Lung Cancer Brain Metastases
Status: Active
Location: 3 locations
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Status: Active
Location: 2 locations
Defactinib and Avutometinib with or without Encorafenib for the Treatment of Patients with Brain Metastases from Cutaneous Melanoma
Status: Active
Location: 2 locations
Alectinib Alone or in Combination with Stereotactic Radiosurgery for Controlling Disease in Patients with Stage IV Non-small Cell Lung Cancer and Brain Metastases
Status: Active
Location: 2 locations
Stereotactic Radiosurgery, Abemaciclib, and Endocrine Therapy for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases
Status: Active
Location: 2 locations
Genu-Sparing Whole-Brain Radiotherapy in Preserving Cognition and Neuropsychiatric Functioning in Patients with Solid Tumors with Brain Metastases
Status: Active
Location: 6 locations
Same Day Stereotactic Radiation Planning and Treatment with Margin Reduction for Residual or Recurrent Brain Metastases
Status: Active
Location: 2 locations
GLIADEL or Stereotactic Radiosurgery after Surgery for the Treatment of Metastatic Brain Tumor
Status: Active
Location: University of Nebraska Medical Center, Omaha, Nebraska
Tucatinib and T-DM1 for the Treatment of Patients with HER2-Positive Metastatic Solid Tumors and Brain Metastases, TUCATEMEB Study
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Post-Operative Dosing of Dexamethasone in Patients with Brain Tumors after a Craniotomy, PODS trial
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Consolidative Stereotactic Radiosurgery for the Treatment of Brain Metastases in Melanoma and Solid Tumor Cancer Patients, EXCLAIM Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Nivolumab in Combination with Relatlimab in Treating Patients with Active Melanoma Brain Metastases
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Relatlimab, Nivolumab, and Ipilimumab for the Treatment of Unresectable or Metastatic Melanoma with Asymptomatic or Symptomatic Brain Metastases
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Nivolumab, Ipilimumab, and Cabozantinib for the Treatment of Untreated Renal Cell Carcinoma with Brain Metastases
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tiragolumab with Carboplatin, Pemetrexed, and Atezolizumab for the Treatment of Non-squamous Non-small Cell Lung Cancer and Untreated Brain Metastases
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Pembrolizumab and Lenvatinib for the Treatment of Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, and Other Tumors with Brain Metastases
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Niraparib and Dostarlimab for the Treatment of Brain Metastases in Patients with Advanced Cancers, STARLET Study
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Cell Therapy for the Treatment of Locally Advanced, Metastatic, or Recurrent Solid Cancers
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Radiosurgery before Surgery in Treating Patients with Brain Metastases That Can Be Removed by Surgery
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Stereotactic Radiation with Sacituzumab Govitecan and Zimberelimab for the Treatment of Patients with Metastatic Triple Negative Breast Cancer with Brain Metastases, TARGET-TNBC Trial
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Stereotactic Radiosurgery in Treating Participants with Brain Metastases and Studying Their Neurocognitive Decline
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas